cDC1s have emerged as key players in cross-priming of anti-tumor CD8+ T cells and in the response to cancer immunotherapy (Broz et al., 2014; Hildner et al., 2008; Salmon et al., 2016; Sánchez-Paulete et al., 2016; Spranger et al., 2017). Here, CD8A is linked to neoplasm.